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The patterns of risk association between circulating levels of insulin-like growth factor (IGF)-I, and its main binding protein, IGFBP-3,
differ between smoking and nonsmoking-related cancers. To investigate this observation further, we measured serum IGF-I, IGF-II and
IGF-binding protein-3 concentrations in 232 men and 210 women (aged 55–64 years), and related peptide levels to smoking
characteristics. Current smoking was associated with significant reductions in mean IGFBP-3 levels in men assessed by the number of
cigarettes smoked daily (Ptrend¼0.007) and pack-years smoked (Ptrend¼0.03). Mean IGF-I levels decreased with increasing cigarette
use in men (Ptrend¼0.11). There were no patterns of association between smoking and IGF peptides in women. For male former vs
never smokers, there were no differences in mean IGF-I and IGFBP-3 concentrations, suggesting that smoking cessation is associated
with normalisation of peptide concentrations.
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Insulin-like growth factor-one (IGF-I) is a multifunctional
regulatory peptide important in tumour cell growth and survival
(Jones and Clemmons, 1995). In the circulation, IGF-I is
predominantly bound (490%) to the major insulin-like growth
factor-binding protein, IGFBP-3 (Clemmons, 1997). Unlike most
other growth factors, the IGFs have classical endocrine as well as
local paracrine influences on cell behaviour (Rajaram et al, 1997).
Concentrations of circulating total IGF-I and IGFBP-3 are
influenced by growth hormone, age (levels decline with age after
puberty), gender and nutritional status (Thissen et al, 1994; Juul,
2003). Nevertheless, measurement of circulating IGF peptides
levels can be used as a marker of the general body stores (Holly
and Hughes, 1994).
Across the general population, there are wide interindividual
variations in IGF-I and IGFBP-3 concentrations, which may impact
upon cancer risk (Pollak, 2000; Yu and Rohan, 2000). In a recent
systematic review and meta-regression analysis of 21 studies, we
determined the associations between circulating IGF-I and IGFBP-
3 levels and cancer risk (Renehan et al, 2004), and demonstrated
that the patterns of association differed between smoking and
nonsmoking-related cancer. Specifically, total IGF-I concentrations
are positively associated with the risk of prostate, colorectal and
pre-menopausal breast cancers, but not lung cancer, while total
IGFBP-3 concentrations are positively associated with the risk of
pre-menopausal breast cancer, and, after excluding a recruitment-
bias study, inversely associated with lung cancer risk. A further
population-based study reported that IGFBP-3 concentrations are
inversely associated with increased risk of lung cancer mortality,
but noted no association with serum IGF-I levels (Wakai et al,
2002). In light of these epidemiological observations, we hypothe-
sised that cigarette smoking may influence IGF physiology. Thus,
the aim of this study was to determine the relationships of serum
IGF-I, IGF-II and IGFBP-3 with characteristics of smoking
exposure.
MATERIALS AND METHODS
Study design
Using a cross-sectional design, we studied 232 men and 210
women attending one centre (1998–99) within the Flexi-Scope
colorectal cancer screening trial (Flexi-Scope-Trial-Collaborators,
2002). Participants were healthy ambulatory individuals aged 55–
64 years, invited by open invitation from general medical
practitioner registries. With Ethics Committee approval and after
obtaining informed consent, a trained researcher interviewed
participants. Smoking exposure was evaluated using a modifica-
tion of the European Prospective Investigation into Cancer (EPIC)
study questionnaire (Sargeant et al, 2001), and individuals
categorised as never, former and current smokers. Computed
exposure variables included pack-years smoked, that is, number of
packs (one pack¼20 cigarettes) smoked per day multiplied by the
number of years smoked. Participants were questioned about
medical history and defined as having major illness in accordance
with EPIC study criteria (Sargeant et al, 2001) (see footnote to
Table 1). Hormonal replacement therapy (HRT) use in women was
also recorded. Details of alcohol consumption, physical activity
and diet were not available. For each participant, height and weight
were measured, and body mass index (BMI) accordingly calculated
as weight/height
2 (kgm
 2).
Blood collection
Blood was obtained in clotted tubes and immediately transported
to the laboratory. Serum was isolated by centrifugation at
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y3000r.p.m. for 10min at room temperature and stored at  801C
before analyte determination. Within the study, several quality
control tests were performed, which demonstrated that: (i)
repeated analyte sampling over short periods in healthy indivi-
duals showed minimal variation; (ii) time from venepuncture to
processing had little impact and (iii) there was long-term stability
at  801C storage (Renehan, 2004).
Measurements of IGF-I, IGF-II and IGFBP-3
Serum IGF-I concentrations were measured, following acid–
alcohol extraction, by an established in-house radioimmunoassay
(Renehan et al, 2000b, 2001). Serum IGF-II and IGFBP-3 levels
were determined using a commercially available immuno-radio-
metric assays kit (Diagnostic Systems Laboratories, Inc. Webster,
TX, USA). All determinants were measured in duplicate blind to
cigarette and gender status. The IGF-I/IGFBP-3 molar ratio was
calculated using the conversion: 1ngml
 1 is 0.130nmoll
 1 for
IGF-I and 0.036nmoll
 1 for IGFBP-3. The coefficients of variation
(CVs) for intra- and inter-assay testing were less than 5 and 10%,
respectively (Renehan et al, 2003).
External validity
Studies from the Flexi-Scope Trial have shown that the distribution
across social classes is broadly representative of the general
population (McCaffery et al, 2002). In addition, baseline char-
acteristics of this study cohort by smoking status were similar to
those reported for age-matched UK populations (Appendices A1
and B1).
Statistical analysis
Data were analysed separately for men and women as we
previously reported significant differences in mean IGF-I, IGF-II
and IGFBP-3 concentrations by gender (Renehan et al, 2000b). All
analytes were parametrically distributed (Kolmogorov–Smirnov
test), and thus the principal results were expressed as means and
standard deviations (s.d.). For descriptive analysis, Student’s t-
tests, one-way ANOVA and chi-squared (w
2) tests were used.
With smoking characteristics as the principal factor of interest,
we evaluated for trends across serum IGF concentrations using
linear regression models. As factors of interest may have trends in
opposite directions in current vs former smokers (e.g. BMI) (Chao
et al, 2000; DoH, 2000; Sargeant et al, 2001), we analysed the data
separately for never (referent) vs current smokers, and never vs
former smokers. As the distributions for quantifying smoking
exposure were not continuous – for example, participants tended
to report the number of cigarettes smoked per day in multiples of
five – we determined the ranks for these variables based on
arbitrary cutoff points. Thus, for instance, the average number of
cigarettes per day was ranked as 1, 2 and 3, for o5, 15–24 and
X25 cigarettes smoked per day, respectively. Never smokers were
then denoted as zero and models constructed. Model A
(univariate) was unadjusted with dependent variables IGF-I, IGF-
II, IGFBP-3 and the IGF-I/IGFBP-3 molar ratio. Model B was
adjusted for age and ethnicity as IGF levels decline with age after
puberty (Juul, 2003) and vary between ethnic groups (Platz et al,
1999). We included both BMI and height in this model to capture
information on both body composition and body size. For women,
we included current (within past 6 months) use of HRT as its use is
associated with reductions in mean IGF-I and IGFBP-3 concentra-
tions (Leung et al, 2004). To accommodate the opposing effects of
IGF-I and IGFBP-3 (r¼0.59, Po0.001), and IGF-II and IGFBP-3
(r¼0.61, Po0.001), model C included adjustments for IGFBP-3
where IGF-I and IGF-II were dependent variables, and for IGF-I
where IGFBP-3 was the dependent variable. Results were reported
as b coefficients, and their standard errors (s.e.) and the total
model r
2 were calculated to provide a sense of the model variability
and strength of fit (STATA version 7.0: StataCorp, College Station,
TX, USA).
RESULTS
The study baseline characteristics are shown in Table 1. Of the 442
participants, 19% of men and 19% of women were current
smokers; 41% of men and 29% of women were former smokers at
the time of blood sampling. As reported in other studies (Chao
et al, 2000; DoH, 2000; Sargeant et al, 2001), current smoking was
associated with lower BMI values in both genders, while former
smoking was associated with higher BMI values, compared to that
for never smoking. Men tended to start smoking at an earlier age,
smoke more cigarettes per day and had greater pack-years of
smoking, compared with women. In all, 40% (83 out of 210) of
women were current HRT users.
Table 1 Characteristics of 232 men and 210 women, aged 55–64 years
Never
smokers
Former
smokers
Current
smokers
Men
Number of participants 91 96 45
Mean (s.d.)
Age (years) 60.8 (2.8) 60.8 (2.8) 60.5 (2.6)
Height (cm) 175 (7.1) 176.1 (6.5) 175 (6.8)
Weight (kg) 80.4 (13.6) 82.6 (10.6) 79.6 (12.4)
BMI (kgm
 2)
a 26.3 (4.5) 26.6 (3.2) 26.0 (3.4)
Age started smoking (years) — 17.2 (3.3) 20.1 (7.5)
Duration smoking (years) — 22.5 (9.7) 40.4 (8.1)
Cigarettes per day — 20.4 (14.4) 17.0 (10.0)
Pack-years of cigarette
smoking
b
— 23.7 (20.2) 33.9 (20.5)
Age when quit smoking
(years)
— 39.6 (9.2) —
Numbers (%)
Caucasian 86 (95) 87 (91) 41 (91)
Current aspirin use 15 (17) 18 (19) 9 (20)
Major illness
c 23 (25) 42 (44) 12 (27)
Diabetes mellitus 3 (3) 9 (9) 1 (2)
Women
Number of participants 110 60 40
Mean (s.d.)
Age (years) 59.7 (2.7) 60.5 (2.7) 59.6 (2.6)
Height (cm) 162 (6) 162 (7) 163 (7.1)
Weight (kg) 69.5 (10.8) 70.8 (13.9) 68.2 (10.1)
BMI (kgm
 2)
a 26.6 (4.3) 26.9 (5.3) 25.8 (3.9)
Age started smoking (years) — 19.5 (3.9) 19.9 (8.3)
Duration smoking (years) — 21.0 (10.4) 39.5 (8.5)
Cigarettes per day — 12.4 (6.7) 13.9 (7.9)
Pack-years of cigarette
smoking
b
— 13.9 (12.5) 28.3 (18.2)
Age when quit smoking
(years)
— 40.5 (10.3) —
Numbers (%)
Caucasian 106 (96) 58 (97) 40 (100)
Current aspirin use 13 (12) 5 (8) 5 (13)
Major illness
c 29 (26) 14 (23) 9 (23)
Diabetes mellitus 3 (3) 2 (2) 1 (3)
Current HRT user
d 42 (38) 23 (38) 18 (45)
Ever HRT user 50 (46) 29 (48) 20 (50)
s.d.¼standard deviation.
aBMI¼body mass index.
bPack-years presented as median
(inter-quartile range).
cMajor illness included: high blood pressure (hypertension)
requiring treatment with drugs, high blood cholesterol (hyperlipidemia), angina, heart
attack (myocardial infarction), stroke, other vascular disease (peripheral vascular
disease), diabetes mellitus (excluding gestational diabetes) and cancer.
dHRT¼hor-
hormonal replacement therapy; Current use defined as within the past 6 months.
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calculated IGF-I/IGFBP-3 molar ratio according to gender and
smoking status are shown in Table 2. With never smokers as
referents, mean levels for IGF-I were higher (mean
difference¼26.1, 95% confidence interval, 9.7–42.4ngml
 1),
IGF-II were lower ( 59.3,  112.0 to  6.7ngml
 1), IGFBP-3 were
lower ( 89.6,  253.3 to 74.1ngml
 1), and IGF-I/IGFBP-3 ratio
were higher (0.028, 0.007–0.013) in men compared with women.
Among men, smoking was associated with nonsignificant reduc-
tions in mean serum IGF-I levels, but significant reductions in
mean IGFBP-3 levels (1-ANOVA, P¼0.04). As expected, the
current use of HRT in women was associated with significant
reductions in mean serum IGF-I (Student’s t-test, P¼0.003) and
IGFBP-3 (P¼0.01) concentrations. After taking account of HRT
status, there was no significant association between mean IGF-I or
IGFBP-3 concentrations and smoking habit in women. There were
no distinct patterns of association between smoking and serum
IGF-II.
We evaluated for trends in IGF peptide concentrations and
smoking exposure (Table 3). Among male current smokers, and
taking never smokers as zero cigarettes, there were significant
reductions in mean IGFBP-3 concentrations assessed as the
number of cigarettes smoked per day (unadjusted: b¼ 144,
s.e.¼51, Ptrend¼0.005, r
2¼0.057) and as pack-years smoked
(b¼ 108, s.e.¼46, Ptrend¼0.02, r
2¼0.040). These significant
trends remained after adjustments for age, ethnicity, height, BMI
and IGF-I (fully adjusted: b¼ 113, s.e.¼41, Ptrend¼0.007,
r
2¼0.421 and b¼ 82, s.e.¼37, Ptrend¼0.03, r
2¼0.410, respec-
tively). Among female current smokers, there were nonsignificant
reductions in mean IGFBP-3 levels with increasing smoking
exposure (fully adjusted: b¼ 48, s.e.¼42, Ptrend¼0.25,
r
2¼0.356 and b¼ 51, s.e.¼43, Ptrend¼0.24, r
2¼0.356 for
cigarettes per day and pack-years, respectively). For men, there
was a nonsignificant trend towards reduced mean IGF-I levels with
increasing smoking exposure (Ptrend¼0.11), but no association
after adjustment for IGFBP-3. There were no trends for IGF-I in
women, and IGF-II or the IGF-I/IGFBP-3 ratio in both genders.
Data from the UK Doctor’s study (Peto et al, 2000) have shown
that the risk of smoking-related cancers returns towards general
population risk levels with increasing duration since smoking
cessation. To test the relevance of this observation to circulating
IGFs, we evaluated the trends in mean analyte levels by categories
of years since quit smoking, and age when quit smoking (Table 4).
In general, mean values for serum IGF-I, IGF-II, IGFBP-3 and IGF-
I/IGFBP-3 ratios demonstrated no difference among former
smokers compared to current smokers. Mean IGFBP-3 levels in
men who recently stopped smoking were lower than those in never
smokers, but this did not reach statistical significance.
DISCUSSION
Cigarette smoking was associated with significant exposure-related
reductions (up to 13%) in mean serum IGFBP-3 levels in men (and
to a lesser extent in women), an observation which may be relevant
for smoking-related tumour development. Smoking tended to
decrease mean IGF-I levels in men, but these changes may reflect
parallel reductions in IGFBP-3 concentrations. Mean IGF-I and
IGFBP-3 levels were similar for former smokers and never
smokers, suggesting that these markers of cancer risk normalise
following smoking cessation.
An advantage of this study was the narrow age-defined
population-based cohort, as we and others have shown that
circulating levels of IGF peptides change over a wide age range in a
nonlinear fashion (Renehan et al, 2000a; Juul, 2003). Comparing
never vs current smokers, and never vs former smokers, was
another key study feature, as factors of interest may influence IGF
physiology in opposite directions in different smoking groups. In
addition, in previous studies, smoking exposure has often been
treated as an ordinal scale variable (never, former smoker, current
smoker) without taking account of quantities smoked and the time
period of exposure. Having taken account of these factors, the
current study demonstrated significant exposure-related trends in
IGFBP-3 levels.
The relatively small numbers in the smoking categories and the
cross-sectional design with once-only analyte measurements were
potential disadvantages of the study. Further limitations were the
lack of data for alcohol consumption, dietary factors and physical
activity. For alcohol consumption, a factor known to be associated
with cigarette smoking, studies have shown inconsistent relation-
ships with serum IGF-I concentrations – increase (Goodman
Gruen and Barrett Connor, 1997; Kaklamani et al, 1999), decrease
Table 2 Serum concentrations of IGF-I, IGF-II, IGFBP-3 and the molar IGF-I/ IGFBP-3 ratio by smoking status in men and women
Mean concentrations (s.d.)
IGF-I (ngml
 1) IGF-II (ngml
 1) IGFBP-3 (ngml
 1) IGF-I/IGFBP-3
Men
Smoking status
Never smoker 200 (62) 833 (181) 3192 (549) 0.225 (0.053)
Former smoker 189 (73) 834 (205) 3099 (657) 0.219 (0.059)
Current smoker 183 (67) 806 (192) 2903 (615) 0.229 (0.061)
P (1-ANOVA) 0.32 0.71 0.04 0.57
Women
HRT within 6 months
No (n¼127) 178 (52) 883 (187) 3355 (588) 0.198 (0.050)
Yes (n¼83) 156 (50) 877 (189) 3134 (636) 0.186 (0.048)
P (Student’s t-test) 0.003 0.81 0.01 0.09
Smoking status No HRT HRT No HRT HRT
Never smoker 181 (56) 163 (54) 892 (194) 3368 (611) 3142 (603) 0.198 (0.051)
Former smoker 176 (52) 149 (37) 868 (174) 3388 (611) 3145 (607) 0.188 (0.046)
Current smoker 172 (44) 151 (55) 868 (190) 3258 (483) 3101 (774) 0.191 (0.50)
P (1-ANOVA) 0.77 0.51 0.65 0.69 0.97 0.43
s.d.¼standard deviation. HRT¼hormonal replacement therapy. Current HRT use defined as within the past 6 months. Molar ratio conversion: 1ngml
 1 is 0.130nmoll
 1 for
IGF-I and 0.036nmoll
 1 for IGFBP-3.
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y(Teramukai et al, 2002) or no change (Holmes et al, 2002a) – but
mainly positive correlations with IGFBP-3 (Holmes et al, 2002a;
Teramukai et al, 2002). Recent reports suggest that plant-based
diets (Holmes et al, 2002b), high-protein diets (Allen et al, 2003)
and milk consumption (Ma et al, 2001; Gunnell et al, 2003) may be
important determinants of circulating IGF peptide levels. However,
cross-sectional studies fail to demonstrate consistent associations
between circulating IGF peptides and level of physical activity
(Landin Wilhelmsen et al, 1994; Voskuil et al, 2001; Holmes et al,
2002a; Teramukai et al, 2002). These need to be considered in
future studies.
One other study (Kaklamani et al, 1999) has specifically
determined the relationships between serum IGF peptides and
smoking, but was limited to 130 individuals (only 22 current
smokers) across a wide age range, men and women analysed
together, and the regression analyses of relationships with smoking
exposure (as a continuous variable) were limited to current
smokers only, without taking account of never smokers (i.e. zero).
Additional studies have determined IGF–smoking relationships
within wider analyses of associations with lifestyle and/or
anthropometric factors. Despite these differences in design, there
are emerging consistent observations: (i) across different popula-
tions – Japanese (Teramukai et al, 2002), Greek (Kaklamani et al,
1999), American (Chang et al, 2002), United Kingdom (present
study) – there are reductions in mean IGFBP-3 levels with smoking
in men, but not in women (Chang et al, 2002; Holmes et al, 2002a);
(ii) associations between serum IGF-I and cigarette smoking are
generally inverse in men (Landin Wilhelmsen et al, 1994;
Teramukai et al, 2002), but weak (Holmes et al, 2002a) or absent
(Landin Wilhelmsen et al, 1994) in women. However, in post-
menopausal women, the expected reductions in mean serum IGF-I
levels associated with HRT usage may be greater among current
smokers (Chang et al, 2002). Unique to our study, we showed that
the trend towards reduced mean IGF-I levels with increasing
smoking was attenuated after adjustment for IGFBP-3, suggesting
that these changes may be dependent on parallel reductions in
IGFBP-3 concentrations.
What are the implications for cancer mechanisms? For lung
cancer, the findings of the current study are consistent with our
meta-analysis (Renehan et al, 2004) that reported no association
with circulating IGF-I but a significant inverse association with
IGFBP-3 (after excluding a heavy smokers-only study). An inverse
role for IGFBP-3 in lung tumorigenesis is supported by the
observation that constitutive expression of IGFBP-3 inhibits the
growth of non-small-cell lung cancer (Lee et al, 2002). Yet, for pre-
menopausal breast cancer, there is a positive association between
circulating IGFBP-3 and cancer risk (Renehan et al, 2004). These
apparent paradoxes are not unexpected as the cellular functions of
Table 3 Serum concentrations of IGF-I, IGF-II, IGFBP-3 and the molar IGF-I/ IGFBP-3 ratio by smoking characteristics in men and women
Mean concentrations (s.d.)
n IGF-I (ngml
 1) IGF-II (ngml
 1) IGFBP-3 (ngml
 1) IGF-I/IGFBP-3
Men
Number of cigarettes daily
Never (zero) 91 200 (62) 833 (181) 3192 (549) 0.225 (0.053)
1–14 cigarettes 18 180 (68) 799 (209) 2959 (562) 0.220 (0.065)
15–24 cigarettes 17 190 (54) 799 (165) 2921 (714) 0.237 (0.053)
X25 cigarettes 10 178 (77) 831 (211) 2771 (566) 0.233 (0.071)
Model A, P for trend 0.20 0.61 0.005 0.51
Model B, P for trend 0.11 0.43 0.002 0.62
Model C, P for trend 0.76 0.14 0.007 —
Current smokers, pack-years
Never (zero) 91 200 (62) 833 (181) 3192 (549) 0.225 (0.053)
1–20 15 181 (70) 839 (179) 2929 (623) 0.223 (0.064)
21–39 13 184 (67) 690 (194) 2794 (596) 0.237 (0.063)
X40 17 185 (61) 867 (172) 2963 (649) 0.229 (0.061)
Model A, P for trend 0.22 0.65 0.02 0.66
Model B, P for trend 0.15 0.48 0.009 0.70
Model C, P for trend 0.87 0.24 0.03 —
Women
Number of cigarettes daily
Never (zero) 110 174 (56) 892 (194) 3282 (615) 0.192 (0.050)
1–9 cigarettes 10 154 (47) 883 (124) 3347 (403) 0.168 (0.039)
10–19 cigarettes 17 165 (49) 873 (191) 3221 (576) 0.194 (0.050)
X20 cigarettes 13 167 (56) 850 (237) 3020 (811) 0.209 (0.054)
Model A, P for trend 0.42 0.43 0.21 0.95
Model B, P for trend 0.49 0.46 0.18 0.79
Model C, P for trend 0.94 0.86 0.25 —
Current smokers, pack-years
Never (zero) 110 174 (56) 892 (194) 3282 (615) 0.192 (0.050)
1–18 13 163 (46) 893 (137) 3345 (473) 0.175 (0.043)
19–38 14 159 (51) 857 (194) 3196 (558) 0.179 (0.048)
X39 13 167 (56) 850 (237) 3020 (811) 0.203 (0.052)
Model A, P for trend 0.35 0.38 0.19 0.95
Model B, P for trend 0.47 0.41 0.17 0.81
Model C, P for trend 0.94 0.92 0.24 —
s.d.¼standard deviation. Pack-years were divided into tertiles based on the distribution of all current smokers for men and women. Multiple linear regression model A:
unadjusted. Model B: adjusted for age, ethnicity, height, body mass index and current HRT status in women. Model C: adjusted for age, ethnicity, height, body mass index, current
HRT status in women and IGFBP-3 for IGF-I and IGF-II as dependent variables, and IGF-I for IGFBP-3 as dependent variable.
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environment, may be inhibitory (through sequestration of IGF
ligand), antiproliferative and proapoptotic (Firth and Baxter, 2002)
or antiapoptotic (McCaig et al, 2002) via IGF-independent
pathways. Whereas some authors (Pollak, 2000; Yu and Rohan,
2000) have hypothesised that the relative levels of IGF-I to IGFBP-3
may be important for cancer risk, the absolute quantities
(reflecting total body stores) may be more pertinent, remembering
that IGFBP-3 circulates in molar concentrations considerably (five-
fold) greater than IGF-I.
The study findings suggest (albeit indirectly) that serum IGF-I
and IGFBP-3 levels normalise after smoking cessation, an
observation that is clearly relevant to cancer prevention. However,
a clear understanding of the ‘ups and downs’ of IGF-I and IGFBP-3
is required. Thus, for example, cancer prevention trials (McTier-
nan, 2003) are currently being designed to modulate circulating
IGF-I and IGFBP-3 as biomarkers of cancer risk, and paradoxical
results may be predicted for nonsmokers vs smokers – an increase
in serum IGF-I levels after smoking cessation may simply reflect
peptide normalisation rather than represent a prediction of
increased cancer risk.
The reasons why smoking induces reductions in IGFBP-3 levels
and why there are gender differences are unclear. However, the
merit of this study is that it focuses attention on smoking as a
modifiable influence of circulating IGF peptides, surrogate
markers of common cancer risk.
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Aged 35–44 years 31 198 (88) 876 (156) 3150 (567) 0.226 (0.072)
Aged 45 years and after 29 179 (72) 838 (235) 2958 (665) 0.217 (0.055)
P for trend
a 0.67 0.02 0.39 0.85
Women
Current smokers, pack-years
Never (zero) 110 174 (56) 892 (194) 3282 (615) 0.198 (0.051)
X20 years 33 164 (51) 861 (184) 3269 (651) 0.188 (0.053)
10–19 years 13 176 (49) 868 (173) 3461 (600) 0.188 (0.034)
Less than 10 years 14 160 (46) 884 (161) 3201 (553) 0.187 (0.044)
P for trend
b 0.24 0.49 0.62 0.21
Age when quit smoking
Never 110 174 (56) 892 (194) 3282 (615) 0.198 (0.051)
Before age 35 years 22 164 (51) 881 (190) 3334 (700) 0.185 (0.048)
Aged 35–44 years 18 166 (55) 827 (183) 3261 (653) 0.189 (0.053)
Aged 45 years and after 20 167 (42) 891 (148) 3283 (502) 0.190 (0.040)
P for trend
b 0.31 0.39 0.70 0.28
s.d.¼standard deviation.
aModels adjusted for age, ethnicity, height, body mass index and IGFBP-3 for IGF-I and IGF-II as dependent variables, and IGF-I for IGFBP-3 as dependent
variable.
bModels adjusted for age, ethnicity, height, body mass index, current HRT status and IGFBP-3 for IGF-I and IGF-II as dependent variables, and IGF-I for IGFBP-3 as
dependent variable.
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Appendix A1
A comparison of the baseline characteristics of the study
participants with UK population is given in Table A1.
Appendix B1
A comparison of the baseline characteristics of study participants
with EPIC-Norfolk study is given in Table B1.
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Manchester study (55–64
years)
UK population (55–64 years)
(Health Survey for England) P-value
a
Numbers (%)
Men N¼232 N¼985
b
Never smoker 91 (39) 315 (32) 0.04
Former smokers 96 (41) 443 (45) 0.36
Current smokers 45 (19) 226 (23) 0.24
Women N¼210 N¼1147
b
Never smoker 110 (52) 573 (50) 0.57
Former smokers 60 (29) 287 (25) 0.32
Current smokers 40 (19) 287 (25) 0.08
Number of cigarettes smoked in current smokers
Men N¼232 N¼231
c
Under 10 cigarettes 32 (14) 42 (18)
10 to under 20 cigarettes 84 (36) 85 (37)
20 and over 116 (50) 104 (45)
Mean (s.e.) 17.0 (1.5) 18.2 (0.75)
Women N¼210 N¼289
c
Under 10 cigarettes 67 (27) 72 (25)
10 to under 20 cigarettes 80 (38) 124 (43)
20 and over 73 (35) 93 (32)
Mean (s.e.) 13.9 (1.4) 14.3 (0.50)
Values in parentheses are percentages unless otherwise stated. s.e.¼standard error.
aw
2 test.
bData from Health Survey of England, 1998 Cardiovascular Disease, Table 3.13.
cData from Health Survey of England, 1998 Cardiovascular Disease, Table 3.22 (www.official-documents.co.uk/document/doh/survey98).
Table B1
Manchester study EPIC-Norfolk study
Never
smoker
Former
smoker
Current smoker
Never
smoker
Former
smoker
Current smoker
o15 cigday
 1 X15 cigday
 1 o15 cigday
 1 X15 cigday
 1
Men
No. of participants (%) 91 (39) 96 (41) 18 (8) 27 (12) 918 (34) 1463 (54) 116 (4) 20 (8)
Mean (s.d.)
Age (years) 60.8 (2.8) 60.7 (2.8) 61.2 (2.8) 60.4 (2.5) 58.0 (8.0) 60.5 (8.4) 59.0 (8.4) 56.8 (8.0)
BMI (kgm
 2) 26.3 (4.5) 26.6 (3.2) 25.4 (2.6) 26.3 (3.8) 26.3 (3.2) 27.0 (3.3) 26.3 (3.7) 25.7 (3.2)
Pack-years smoking
a — 19 (9–32) 18 (11–21) 43 (35–48) — 11 (3–23) 18 (13–28) 30.5 (23–37)
Numbers (%)
Major illness
b 23 (25) 42 (44) 4 (22) 8 (30) 250 (27) 513 (35) 34 (29) 43 (21)
Women
No. of participants (%) 110 (52) 60 (29) 19 (9) 21 (10) 1894 (56) 1127 (33) 191 (6) 173 (5)
Mean (s.d.)
Age (years) 59.7 (2.7) 60.5 (2.7) 59.8 (2.4) 59.3 (2.7) 58.9 (8.2) 59.8 (8.7) 58.0 (8.7) 55.1 (6.7)
BMI (kgm
 2) 26.6 (4.3) 26.9 (5.3) 25.8 (4.3) 25.8 (3.5) 26.1 (4.2) 27.0 (4.7) 25.1 (4.1) 25.3 (4.1)
Pack-years smoking
a — 11 (5–19) 11 (6–20) 40 (33–45) — 5 (1–14) 13 (6–18) 25 (19–30)
Numbers (%)
Major illness
b 29 (26) 14 (23) 5 (26) 4 (19) 501 (27) 326 (29) 36 (19) 35 (20)
Current HRT use 42 (38) 23 (38) 8 (42) 10 (48) 291 (20) 230 (26) 38 (26) 37 (29)
s.d.¼standard deviation.
aPack-years presented as median (inter-quartile range).
bMajor illness included: high blood pressure (hypertension) requiring treatment with drugs, high
blood cholesterol (hyperlipidemia), angina, heart attack (myocardial infarction), stroke, other vascular disease (peripheral vascular disease), diabetes mellitus (excluding gestational
diabetes) and cancer.
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